MAIT cells in hidradenitis suppurativa study
Part of Infections, Skin clinical trials.
This trial looks at a type of immune cell (MAIT cells) in people with hidradenitis suppurativa (a skin condition causing painful bumps). It aims to understand how these cells work and how they relate to treatments like adalimumab, secukinumab, or bimekizumab. You may be able to join if you have moderate-to-severe HS and are about to start one of these treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have had hidradenitis suppurativa for at least 6 months.
- Your HS must be moderate to severe (based on a specific score).
- You must be scheduled to start treatment with adalimumab, secukinumab, or bimekizumab within 7 days.
- You must have a negative test for tuberculosis and no active infections like HIV or hepatitis.
- You cannot be pregnant, breastfeeding, or on certain immune-suppressing medicines in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medicine, SPY072, for adults with moderate to severe hidradenitis suppurativa (also known as HS), a skin condition that causes painful lumps and sores. If you join, you'll help see if this treatment is safe and effective.
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.
This study tests if a drug called secukinumab (a self-injected biologic) is safe and effective for adults with moderate-to-severe hidradenitis suppurativa (HS) in China. It may help reduce the number of painful HS lesions.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.